Kalytera Therapeutics to Study Genetic Markers of Osteoporosis in Patients With Prader-Willi Syndrome
MANHATTAN BEACH, CA -- (Marketwired) -- 08/08/16 -- Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has signed a research agreement with Shaare Zedek Medical Center …